Dear Editor, The global crisis of antibiotic resistance demands innovative solutions that transcend traditional approaches to drug development and administration. One such groundbreaking concept is the idea of gene-encoded antibiotics, where the genetic instructions for producing antibiotics are embedded within the DNA of human cells, enabling the body to synthesize these compounds on demand in response to infection. This hypothesis challenges conventional paradigms by shifting antibiotic production from external pharmaceuticals to an internal, biologically regulated system. If realized, this approach could fundamentally transform how we prevent and treat bacterial infections, while significantly reducing the overuse and misuse of antibiotics that drive resistance. The core of this hypothesis lies in the ability of human cells to be genetically engineered to produce antimicrobial peptides (AMPs) or other antibiotic-like molecules when triggered by specific signals, such as the presence of pathogenic bacteria. Advances in synthetic biology and gene-editing technologies, such as CRISPR-Cas9, have made it feasible to introduce synthetic gene circuits into human cells that can detect bacterial infections and respond by producing targeted antimicrobial agents.1 These gene circuits could be designed to activate only in the presence of specific bacterial biomarkers, ensuring precise and localized antibiotic production that minimizes collateral damage to beneficial microbiota. One of the most compelling advantages of gene-encoded antibiotics is their potential to eliminate the need for systemic antibiotic administration. By producing antibiotics directly at the site of infection, this approach could achieve higher local concentrations of the drug while avoiding the widespread exposure that contributes to resistance.2 For example, epithelial cells in the respiratory tract could be engineered to produce AMPs in response to bacterial pneumonia, or immune cells could be programmed to release bacteriocins when encountering antibiotic-resistant pathogens. This targeted delivery system would not only enhance therapeutic efficacy but also reduce the risk of disrupting the body’s microbiome, a common side effect of traditional antibiotics. To explore this hypothesis, I propose a multidisciplinary research framework that integrates synthetic biology, immunology, and microbiology. Key steps could include designing synthetic gene circuits to develop genetic constructs that encode antibiotic production and are responsive to bacterial infection signals. These circuits could be tested in vitro using human cell lines to optimize their specificity and efficiency. Preclinical models utilizing animal models would be essential to evaluate the safety and efficacy of gene-encoded antibiotics in vivo, involving the engineering of specific tissues or immune cells to produce antimicrobial agents and assessing their ability to clear infections without adverse effects. Biomarker identification is another critical step, focusing on unique bacterial biomarkers that can serve as triggers for antibiotic production, ensuring the system is activated only in the presence of pathogenic bacteria and avoiding unnecessary immune activation. Finally, developing safe and efficient delivery mechanisms for synthetic gene circuits to human cells, such as viral vectors or nanoparticle-based systems, would be crucial for the practical application of this technology. One innovative perspective is the potential for gene-encoded antibiotics to evolve alongside bacterial resistance. Unlike static pharmaceutical drugs, gene circuits could be designed to adapt to emerging resistance mechanisms by incorporating modular components that can be updated or replaced as needed. For instance, if a bacterial pathogen develops resistance to a specific AMP, the gene circuit could be reprogrammed to produce a different antimicrobial agent with a novel mode of action.3 This dynamic approach could provide a sustainable solution to the arms race between antibiotics and resistant bacteria. Another groundbreaking idea is the integration of gene-encoded antibiotics with the body’s immune system. Immune cells, such as macrophages or neutrophils, could be engineered to produce antimicrobial agents as part of their natural response to infection. This would create a synergistic effect, where the immune system not only detects and engulfs pathogens but also delivers targeted antibiotic payloads to eliminate them. Such a system could be particularly effective against intracellular bacteria, which are often shielded from traditional antibiotics Figure 1.4Figure 1: Gene-Encoded Antibiotics as an Internal Therapeutic Platform: Engineering Human Cells to Detect Infection and Produce Targeted AntimicrobialsIn conclusion, the concept of gene-encoded antibiotics represents a paradigm shift in our approach to combating bacterial infections and antibiotic resistance. By harnessing the power of synthetic biology and genetic engineering, we can create a dynamic, self-regulating system that produces antibiotics precisely when and where they are needed. This approach has the potential to revolutionize medicine, offering a sustainable and effective solution to one of the greatest challenges of our time. I urge the scientific community to explore this innovative hypothesis, as it holds immense promise for the future of infectious disease treatment. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
Falah Hasan Obayes Al-Khikani (Thu,) studied this question.